2025-522287-32-00CompletedPhase 1
A randomised, double-blind, placebo-controlled phase Ib trial evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple doses of ACD856 in healthy participants
Source: EU CTIS (euclinicaltrials.eu) · Last updated 10 Sept 2025
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 40 (actual)
- First submitted
- 30 Jun 2025
- Start date
- 22 Oct 2025
- Lead sponsor
- AlzeCure Pharma AB
- EU CT number
- 2025-522287-32-00
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 40
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| CTC Clinical Trial Consultants AB | Uppsala | Sweden | Completed |
This page is information, not medical advice. Discuss any trial with your doctor.